17 January 2020
A new report suggests that the neoantigen cancer vaccine market will grow at a compound annual growth rate (CAGR) of 34.69 percent during the forecast period, 2023-2030.
The findings of the ResearchAndMarkets.com analysis indicate the neoantigen cancer vaccine market should generate $227.1 million revenue in 2023, greatly due to the expected launch of first neoantigen vaccine Tedopi in the market. The overall total revenue expected from the market by 2030 is $1,826.1 million.
The key market drivers listed in the report include Roche, Moderna Therapeutics/Merck joint venture and OSE Immunotherapeutics, among many others.
“The real issues with neovaccines are higher cost, turn-around times and limited efficacy. The cost and time to manufacture have come down in the last four years and as technology improves it will come down more,” reveals a ResearchAndMarkets.com expert, suggesting that this is why the market may continue such expansion.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia has expanded the mandatory health insurance program for 2024-2026
29 March 2024
Russian scientists have developed new TB vaccines for both injection and nasal administration.
29 March 2024
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024